NuCana Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat NuCana de winst en omzet met respectievelijk 10.2% en 79.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 20.4% per jaar.

Belangrijke informatie

10.2%

Groei van de winst

20.4%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	79.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqCM:NCNA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-27	N/A	N/A	4
12/31/2025	N/A	-24	N/A	N/A	4
12/31/2024	N/A	-25	N/A	N/A	4
6/30/2024	N/A	-28	-18	-17	N/A
3/31/2024	N/A	-27	-22	-22	N/A
12/31/2023	N/A	-28	-27	-26	N/A
9/30/2023	N/A	-35	-34	-33	N/A
6/30/2023	N/A	-33	-22	-22	N/A
3/31/2023	N/A	-31	-25	-25	N/A
12/31/2022	N/A	-32	-24	-23	N/A
9/30/2022	N/A	-30	-27	-26	N/A
6/30/2022	N/A	-34	-30	-29	N/A
3/31/2022	N/A	-39	-25	-24	N/A
12/31/2021	N/A	-41	-25	-24	N/A
9/30/2021	N/A	-39	-23	-23	N/A
6/30/2021	N/A	-40	-28	-27	N/A
3/31/2021	N/A	-36	-25	-23	N/A
12/31/2020	N/A	-31	-23	-22	N/A
9/30/2020	N/A	-26	-18	-17	N/A
6/30/2020	N/A	-22	-21	-20	N/A
3/31/2020	N/A	-20	-25	-24	N/A
12/31/2019	N/A	-21	-25	-24	N/A
9/30/2019	N/A	-17	-24	-22	N/A
6/30/2019	N/A	-16	-19	-18	N/A
3/31/2019	N/A	-13	-17	-16	N/A
12/31/2018	N/A	-14	-14	-12	N/A
9/30/2018	N/A	-15	-14	-13	N/A
6/30/2018	N/A	-26	-12	-11	N/A
3/31/2018	N/A	-28	N/A	-10	N/A
12/31/2017	N/A	-23	N/A	-9	N/A
9/30/2017	N/A	-20	N/A	-8	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-6	N/A	-9	N/A
12/31/2016	N/A	-6	N/A	-9	N/A
12/31/2015	N/A	-5	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat NCNA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat NCNA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat NCNA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat NCNA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat NCNA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NCNA naar verwachting over 3 jaar hoog zal zijn

NuCana Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.5% to US$4.79

Price target increased by 10% to US$4.38

Price target decreased to US$3.42

Price target decreased to US$4.26

Price target decreased to US$4.26

Price target decreased to US$4.69

Recent updates

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

New minor risk - Shareholder dilution

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven